Retatrutide 10mg

Also known as "Triple G" as it targets three different receptors and hormones (GLP-1, glucagon and GIP) that help balance appetite and metabolism.

Retatrutide is a synthetic 39-amino-acid peptide engineered to bind and activate three distinct receptors simultaneously: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. It belongs to the same broad family as Semaglutide and Tirzepatide, but the addition of glucagon receptor activity makes it mechanistically distinct from anything that came before it.

Retatrutide is currently in Phase 3 clinical trials in humans for obesity and Type 2 diabetes. Phase 2 trial results published in The New England Journal of Medicine in 2023 generated significant attention in both the medical literature and the broader scientific press, and the compound is now widely regarded as the leading next-generation candidate in the incretin class.